Menorrhagia Market

Market Overview:

The 7 major menorrhagia markets reached a value of US$ 970 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,380 Million by 2034, exhibiting a growth rate (CAGR) of 3.26% during 2024-2034.

The menorrhagia market has been comprehensively analyzed in IMARC's new report titled "Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Menorrhagia is a medical term used to describe prolonged or abnormally heavy menstrual bleeding in women. It refers to menstrual periods that involve excessive blood loss, typically exceeding 80 milliliters or lasting longer than seven days. This condition can be distressing and may interfere with a woman's daily activities and quality of life. The common symptoms associated with the ailment include abdominal pain, passing blood clots that are the size of a quarter or bigger, fatigue, weakness, shortness of breath, pale skin, intense cramping, etc. To diagnose menorrhagia, a healthcare provider may review the woman's medical history, conduct a physical examination, and suggest additional tests, such as blood workups, to check for anemia or hormonal imbalances. A transvaginal ultrasound, which involves inserting a probe into the vagina to obtain pictures of the uterus and ovaries to help in identifying structural abnormalities, is also utilized among patients. The doctor may further recommend several diagnostic procedures, including magnetic resonance imaging, hysteroscopy, endometrial biopsy, etc., to rule out other possible causes and validate a diagnosis.

The rising incidences of hormonal imbalances, particularly between estrogen and progesterone, that can disrupt the normal menstrual cycle and lead to heavy bleeding are primarily driving the menorrhagia market. In addition to this, the increasing prevalence of various associated risk factors, such as the use of intrauterine devices, blood clotting disorders, endometrial polyps, etc., is also bolstering the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen sodium, to reduce menstrual bleeding and alleviate pain is acting as another significant growth-inducing factor. Apart from this, the escalating application of minimally invasive endometrial ablation therapy for women who prefer non-hormonal treatment, owing to its numerous advantages, such as rapid recovery time, cost-effectiveness, and improved quality of life, is also creating a positive outlook for the market. Additionally, the emerging popularity of uterine artery embolization techniques for treating this disease condition, since they block the blood flow to the uterus by injecting tiny particles into the uterine arteries, leading to symptom relief, is expected to drive the menorrhagia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the menorrhagia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for menorrhagia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the menorrhagia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the menorrhagia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the menorrhagia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current menorrhagia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the menorrhagia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the menorrhagia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the menorrhagia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of menorrhagia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of menorrhagia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of menorrhagia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with menorrhagia across the seven major markets?
• What is the size of the menorrhagia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of menorrhagia?
• What will be the growth rate of patients across the seven major markets?
   

Menorrhagia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for menorrhagia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the menorrhagia market?
• What are the key regulatory events related to the menorrhagia market?
• What is the structure of clinical trial landscape by status related to the menorrhagia market?
• What is the structure of clinical trial landscape by phase related to the menorrhagia market?
• What is the structure of clinical trial landscape by route of administration related to the menorrhagia market?